Free tool
FAERS Monitor: Lyrica
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022488 or its brand name (Lyrica, Pregabalin). Reports on generic versions are filed under their own applications.
Reports
273,908
Serious
183,607
67% of reports
Hospitalization
78,429
Death reported
22,698
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective27,200
- pain26,508
- fatigue15,853
- dizziness15,031
- nausea14,720
- off label use14,004
- headache13,242
- malaise12,999
- somnolence11,958
- weight increased11,711
- pain in extremity11,488
- fall11,138
- dyspnoea10,618
- diarrhoea10,340
- insomnia9,827
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 351 |
| 2006 | 4,998 |
| 2007 | 2,871 |
| 2008 | 3,560 |
| 2009 | 3,001 |
| 2010 | 13,566 |
| 2011 | 6,904 |
| 2012 | 13,074 |
| 2013 | 14,156 |
| 2014 | 16,247 |
| 2015 | 18,634 |
| 2016 | 19,912 |
| 2017 | 18,062 |
| 2018 | 20,542 |
| 2019 | 22,875 |
| 2020 | 18,930 |
| 2021 | 14,842 |
| 2022 | 13,309 |
| 2023 | 11,934 |
| 2024 | 13,545 |
| 2025 | 13,013 |
| 2026 | 9,577 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,780,251 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 11,958 | 4.8 | 4.7 | 33,998 |
| weight increasedSignal | 11,711 | 4.2 | 4.1 | 27,157 |
| painSignal | 26,508 | 3.4 | 3.4 | 44,690 |
| pain in extremitySignal | 11,488 | 3.1 | 3.0 | 15,673 |
| insomniaSignal | 9,827 | 2.9 | 2.8 | 11,959 |
| fallSignal | 11,138 | 2.6 | 2.6 | 10,993 |
| dizzinessSignal | 15,031 | 2.4 | 2.3 | 11,639 |
| malaiseSignal | 12,999 | 2.3 | 2.3 | 9,620 |
| headache | 13,242 | 1.6 | 1.6 | 3,296 |
| drug ineffective | 27,200 | 1.6 | 1.6 | 6,344 |
| fatigue | 15,853 | 1.6 | 1.6 | 3,388 |
| dyspnoea | 10,618 | 1.4 | 1.4 | 1,488 |
| nausea | 14,720 | 1.4 | 1.4 | 1,989 |
| diarrhoea | 10,340 | 1.2 | 1.2 | 465 |
| off label use | 14,004 | 1.2 | 1.2 | 627 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.